Swedish Pharma is a cutting-edge biotechnology company focusing on the development and commercialization of novel and advanced patch technologies. Our team consists of researchers with extensive experience within the fields of medicine, pharmacology, novel patch technology, drug delivery systems-, development-, and design. Swedish Pharma was founded in 2007 and is currently situated in Stockholm, Sweden.
Trough many years of research our team has developed and patented a highly unique bioadhesive patch technology with significant potential in a wide array of therapeutic areas.
Three significant capabilities distinguishes our technology from that of any of our competitors – making it one of the most versatile patch technologies of today.
Swedish Pharma utilizes the versatility in its patch technology to develop applications within two primary business areas.
Our bioadhesive patch technology has successfully been used in clinical studies as a vehicle of 5ALA in photodynamic treatment (PDT) of superficial neoplastic lesions. PDT is an established and growing therapeutic methodology primarily applied in the treatment of mild to moderate actinic keratosis, a pre-cancerous affliction to the skin normally caused by excessive sun exposure. To find out more about our research results and how it could possibly reinvent the way we use PDT in non-melanoma skin cancer treatment – press here.
Swedish Pharma is always in search for promising strategic partnership agreements to improve the quality of our own project portfolio or contribute to others. We are interested in collaborating with academic and industrial actors in further vertical research and/or commercial projects. Our approach to different collaboration models is pragmatic and we invite open enquiries.
Phone: +46 (0) 707 – 98 36 39